Advances in Therapy

, Volume 31, Issue 8, pp 904–914 | Cite as

Benefit of Endermology on Indurations and Panniculitis/Lipoatrophy During Relapsing–Remitting Multiple Sclerosis Long-Term Treatment with Glatiramer Acetate

  • Carmen Márquez-Rebollo
  • Luisa Vergara-Carrasco
  • Rosa Díaz-Navarro
  • Delia Rubio-Fernández
  • Pablo Francoli-MartínezEmail author
  • Rainel Sánchez-De la Rosa
Original Research



Use of endermology (Endermologie®), which consists of a deep mechanical massage, in patients with multiple sclerosis receiving glatiramer acetate suggested improvements in injection-site indurations and panniculitis/lipoatrophy in our previous pilot experience. We aimed to assess the effect of endermology in a larger population of patients with multiple sclerosis receiving glatiramer acetate in clinical practice.


This was the extension phase of our pilot experience, carried out in patients with relapsing–remitting multiple sclerosis (RRMS) and indurations and/or panniculitis/lipoatrophy associated with long-term glatiramer acetate administration. Patients underwent endermology sessions twice per week, for 6 weeks, according to clinical practice.


Seventy evaluable patients were included (mean age, 42.7 ± 9.3 years; female, 95.7%; mean multiple sclerosis duration, 9.2 ± 8.6 years; mean glatiramer acetate duration, 46.7 ± 29.9 months). Fifty (71.4%) patients showed indurations and 58 (82.9%) panniculitis/lipoatrophy. After 12 endermology sessions, the number of patients with indurations significantly decreased (71.4% vs. 28.6%; p < 0.001), as did the number of their indurations (4.2 ± 3.6 vs. 3.7 ± 3.4; p < 0.001). Although the number of patients with panniculitis/lipoatrophy did not significantly decrease, there was a significant reduction in the number of areas of panniculitis/lipoatrophy (4.3 ± 2.6 vs. 3.9 ± 2.2; p < 0.05). Forty-nine (98.0%) patients with indurations and 57 (98.3%) patients with panniculitis/lipoatrophy felt satisfied/very satisfied with treatment and considered endermology useful/very useful. Endermology was well tolerated, as some pain was reported in eight (11.4%) patients, discomfort in three (4.3%) patients, and local blotch/swelling and transient bruise in one (1.4%) patient each. Endermology enabled glatiramer acetate tolerance to be enhanced in 42 (60.0%) patients.


This project represents the largest experience available supporting the benefit of endermology in the reduction/disappearance of indurations and improvement in panniculitis/lipoatrophy in patients with RRMS receiving long-term glatiramer acetate treatment. Moreover, these benefits also contributed to enhancing glatiramer acetate tolerance.


Endermologie Endermology Glatiramer acetate Induration Lipoatrophy Multiple sclerosis Panniculitis 



Sponsorship and article processing charges for this project were funded by Teva Pharma Spain. We acknowledge the following people for their participation in the project: Jaime Cordero, Leonor Rubio-Hidalgo and Mª Rosario Coll-Carreño at Hospital Regional Universitario Carlos Haya (Málaga, Spain); Agueda Poyato-Roca at Hospital General Universitario Santa Lucía (Cartagena, Spain); Javier Cano-Martínez at Hospital General Universitario Morales Meseguer (Murcia, Spain); Carmen Calles at Hospital Universitari Son Espases (Mallorca, Spain); Clara Rodríguez-del Canto, Héctor Edreira and Lidia Sevane-Fernández at TEVA Pharma S.L.U. (Alcobendas, Spain); Claudio J. Sarabia and Emilio Laveda at Clínica Asestetic Asesoria Médico Estética Integral S.L. (Murcia, Spain). Editorial assistance in the preparation of this manuscript was provided by Esther Álvarez-García and Antonio Torres-Ruiz of Dynamic S.L., and was funded by Teva Pharma Spain. All named authors meet the ICMJE criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole and have given final approval to the version to be published. Rainel Sánchez-De la Rosa is the guarantor for this article. The project data was partially presented in a poster session at: XX Congreso Anual de la Sociedad Española de Enfermería Neurológica: Barcelona (Spain), November 21th–22th, 2013.

Conflict of interest

CM has acted as a board member for Merck and has received honoraria as a consultant and speaker fees and support for traveling to meetings from the following companies: Novartis, Biogen, Merck, Teva, Glaxo, and Genzyme. LVC has acted as a board member for Teva and has received honoraria as a speaker for Novartis, Biogen, Merck, and Teva. RDN has received honoraria as a consultant and speaker fees and support for traveling to meetings from: Novartis, Biogen, Merck, Teva, Glaxo, and Genzyme. DR has received honoraria as a consultant and speaker fees and support for traveling to meetings from the following companies: Novartis, Biogen, Merck, Teva, Glaxo, and Genzyme. PFM is an employee of Teva Pharma Spain, who works at the Medical and HEOR Department. RSR is an employee of Teva Pharma Spain, who works at the Medical and HEOR Department.

Compliance with ethics guidelines

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 2000 and 2008. Informed consent was obtained from all patients included in the project.

Supplementary material

12325_2014_137_MOESM1_ESM.pdf (268 kb)
Supplementary material 1 (PDF 268 kb)


  1. 1.
    Balak DM, Hengstman GJ, Cakmak A, Thio HB. Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review. Mult Scler. 2012;18(12):1705–17.PubMedCrossRefGoogle Scholar
  2. 2.
    Soares Almeida LM, Requena L, Kutzner H, Angulo J, de Sa J, Pignatelli J. Localized panniculitis secondary to subcutaneous glatiramer acetate injections for the treatment of multiple sclerosis: a clinicopathologic and immunohistochemical study. J Am Acad Dermatol. 2006;55(6):968–74.PubMedCrossRefGoogle Scholar
  3. 3.
    Soós N, Shakery K, Mrowietz U. Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis. Am J Clin Dermatol. 2004;5(5):357–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Edgar CM, Brunet DG, Fenton P, McBride EV, Green P. Lipoatrophy in patients with multiple sclerosis on glatiramer acetate. Can J Neurol Sci. 2004;31(1):58–63.PubMedGoogle Scholar
  5. 5.
    LPG Systems. Endermologie. LPG Systems. 2014. Accessed February 2014.
  6. 6.
    Lucassen GW, van der Sluys WLN, van Herk JJ, et al. The effectiveness of massage treatment on cellulite as monitored by ultrasound imaging. Skin Res Technol. 1997;3:154–60.CrossRefGoogle Scholar
  7. 7.
    Watson J, Fodor PB, Cutcliffe B, Sayah D, Shaw W. Physiological effects of Endermologie®: a preliminary report. Aesthetic Surg J. 1999;19(1):27–33.CrossRefGoogle Scholar
  8. 8.
    Adcock D, Paulsen S, Jabour K, Davis S, Nanney LB, Shack RB. Analysis of the effects of deep mechanical massage in the porcine model. Plast Reconstr Surg. 2001;108(1):233–40.PubMedCrossRefGoogle Scholar
  9. 9.
    Innocenzi D, Balzani A, Montesi G, et al. Evidenza delle modificazioni cutanee indotte dalla Tecnica LPG® mediante analise d’immagine. DermoCosmetologia. 2003;2(1):9–15.Google Scholar
  10. 10.
    Marques MA, Combes M, Roussel B, et al. Impact of a mechanical massage on gene expression profile and lipid mobilization in female gluteofemoral adipose tissue. Obes Facts. 2011;4(2):121–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Monteux C, Lafontan M. Use of the microdialysis technique to assess lipolytic responsiveness of femoral adipose tissue after 12 sessions of mechanical massage technique. J Eur Acad Dermatol Venereol. 2008;22(12):1465–70.PubMedCrossRefGoogle Scholar
  12. 12.
    Latrenta GS, Mick SL. Endermologie after external ultrasound-assisted lipoplasty (EUAL) versus EUAL alone. Aesthet Surg J. 2001;21(2):128–35.PubMedCrossRefGoogle Scholar
  13. 13.
    Ersek RA, Mann GE 2nd, Salisbury S, Salisbury AV. Noninvasive mechanical body contouring: a preliminary clinical outcome study. Aesthetic Plast Surg. 1997;21(2):61–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Chang P, Wiseman J, Jacoby T, Salisbury AV, Ersek RA. Noninvasive mechanical body contouring: (Endermologie) a one-year clinical outcome study update. Aesthet Plast Surg. 1998;22(2):145–53.CrossRefGoogle Scholar
  15. 15.
    Ortonne JP, Queille-Roussel C, Duteil L, Emiliozzi C, Zartarian M. Treatment of cellulite: effectiveness and sustained effect at 6 months with Endermologie® demonstrated by several quantitative evaluation methods. Nouv Dermatol. 2004;23:261–9.Google Scholar
  16. 16.
    Kutlubay Z, Songur A, Engin B, Khatib R, Calay Ö, Serdaroglu S. An alternative treatment modality for cellulite: LPG endermologie. J Cosmet Laser Ther. 2013;15(5):266–70.PubMedCrossRefGoogle Scholar
  17. 17.
    Gülec AT. Treatment of cellulite with LPG endermologie. Int J Dermatol. 2009;48(3):265–70.PubMedCrossRefGoogle Scholar
  18. 18.
    Bourgeois JF, Gourgou S, Kramar A, Lagarde JM, Guillot B. A randomized, prospective study using the LPG technique in treating radiation-induced skin fibrosis: clinical and profilometric analysis. Skin Res Technol. 2008;14(1):71–6.PubMedGoogle Scholar
  19. 19.
    Moseley AL, Esplin M, Piller NB, Douglass J. Endermologie (with and without compression bandaging)—a new treatment option for secondary arm lymphedema. Lymphology. 2007;40(3):129–37.PubMedGoogle Scholar
  20. 20.
    Bacci PA, Scatolini M, Leonardi S, Belardi P, Mancini S. Vibroassisted liposuction and endermologie for lipolymphedema. Eur J Lymphol. 2002;10(35–36):16–21.Google Scholar
  21. 21.
    Campisi C, Boccardo F, Zilli A, et al. LPG® technique in the treatment of peripheral lymphedema: clinical preliminary results and perspectives. Eur J Lymphol. 2002;10(35–36):22–3.Google Scholar
  22. 22.
    Worret WI, Jessberger B. Effectiveness of LPG treatment in morphea. J Eur Acad Dermatol Venereol. 2004;18(5):527–30.PubMedCrossRefGoogle Scholar
  23. 23.
    Gordon C, Emiliozzi C, Zartarian M. Use of a mechanical massage technique in the treatment of fibromyalgia: a preliminary study. Arch Phys Med Rehabil. 2006;87(1):145–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Lebrun C, Mondot L, Bertagna M, Calleja A, Cohen M. Endermology: a treatment for injection-induced lipoatrophy in multiple sclerosis patients treated with sub cutaneous glatiramer acetate. Clin Neurol Neurosurg. 2011;113(9):721–4.PubMedCrossRefGoogle Scholar
  25. 25.
    Rubio Fernández D, Rodríguez del Canto C, Marcos Galán V, et al. Contribution of endermology to improving indurations and panniculitis/lipoatrophy at glatiramer acetate injection site. Adv Ther. 2012;29(3):267–75.PubMedCrossRefGoogle Scholar
  26. 26.
    Drago F, Brusati C, Mancardi G, Murialdo A, Rebora A. Localized lipoatrophy after glatiramer acetate injection in patients with remitting-relapsing multiple sclerosis. Arch Dermatol. 1999;135(10):1277–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Mancardi GL, Murialdo A, Drago F, et al. Localized lipoatrophy after prolonged treatment with copolymer 1. J Neurol. 2000;247(3):220–1.PubMedCrossRefGoogle Scholar
  28. 28.
    Benelli L, Berta JL, Cannistra C, Amram P, Benhamou G. Endermologie: humoral repercussions and estrogen interaction. Aesthetic Plast Surg. 1999;23(5):312–5.PubMedCrossRefGoogle Scholar
  29. 29.
    Le Blanc-Louvry I, Costaglioli B, Boulon C, Leroi AM, Ducrotte P. Does mechanical massage of the abdominal wall after colectomy reduce postoperative pain and shorten the duration of ileus? Results of a randomized study. J Gastrointest Surg. 2002;6(1):43–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Khan O, Rieckmann P, Boyko A, et al. Three times weekly glatiramer acetate in relapsing–remitting multiple sclerosis. Ann Neurol. 2013;73(6):705–13.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Healthcare 2014

Authors and Affiliations

  • Carmen Márquez-Rebollo
    • 1
  • Luisa Vergara-Carrasco
    • 2
  • Rosa Díaz-Navarro
    • 3
  • Delia Rubio-Fernández
    • 4
  • Pablo Francoli-Martínez
    • 5
    Email author
  • Rainel Sánchez-De la Rosa
    • 5
  1. 1.Multiple Sclerosis UnitHospital Clínico Universitario Virgen de la ArrixacaEl PalmarSpain
  2. 2.Multiple Sclerosis UnitHospital Regional Universitario Carlos HayaMalagaSpain
  3. 3.Neurology DepartmentHospital Universitari Son EspasesPalma de MallorcaSpain
  4. 4.Neurology DepartmentHospital Universitario de CabueñesGijónSpain
  5. 5.Medical DepartmentTeva Pharma S.L.UAlcobendasSpain

Personalised recommendations